Leukocyte immunoglobulin-like receptor

From Proteopedia

spinqualitylabelsall models Structure of human leukocyte immunoglobulin-like receptor ligand-binding domain (salmon) complex with class I MHC (aqua), β-2 microglobulin (green) and POL polyprotein peptide (pink) (PDB entry 1p7q) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image Leukocyte immunoglobulin-like receptors (LIR) or CD85 have extracellular immunoglobulin domains. LIR modulates a variety of immune cells. LIR interacts with class I MHC molecules[1]. (PDB entry 1p7q). . LILRA2 is an activating receptor that inhibits dendritic cell differentiation. LILRA5 has a role in triggering innate immune responses. LILRB1 interacts with classical and non-classical human leukocyte antigen (HLA) class I molecules[2]. LILRB3 is a target for treatment against acute myeloid leukaemia[3]. LILRB4 suppresses immunity in solid tumors[4]. See also: Immune receptors Receptor

3D structures of leukocyte immunoglobulin-like receptor

Updated on 10-July-2024

References

1. ↑ Thomas R, Matthias T, Witte T. Leukocyte immunoglobulin-like receptors as new players in autoimmunity. Clin Rev Allergy Immunol. 2010 Apr;38(2-3):159-62. doi:, 10.1007/s12016-009-8148-8. PMID:19548123 doi:http://dx.doi.org/10.1007/s12016-009-8148-8
2. ↑ Zeller T, Münnich IA, Windisch R, Hilger P, Schewe DM, Humpe A, Kellner C. Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer. Front Immunol. 2023 Sep 13;14:1240275. PMID:37781391 doi:10.3389/fimmu.2023.1240275
3. ↑ Mai S, Hodges A, Chen HM, Zhang J, Wang YL, Liu Y, Nakatsu F, Wang X, Fang J, Xu Y, Davidov V, Kang K, Pingali SR, Ganguly S, Suzuki M, Konopleva M, Prinzing B, Zu Y, Gottschalk S, Lu Y, Chen SH, Pan PY. LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy. Cancer Res. 2023 Dec 15;83(24):4047-4062. PMID:38098451 doi:10.1158/0008-5472.CAN-22-2483
4. ↑ Sharma N, Atolagbe OT, Ge Z, Allison JP. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J Exp Med. 2021 Jul 5;218(7):e20201811. PMID:33974041 doi:10.1084/jem.20201811